AGF Management’s Viking Therapeutics VKTX Stock Holding History

AGF Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-178,185	Closed	-$4.3M	–	735
2025 Q1	$4.3M	Buy	178,185 +13,922	+8%	+$440K	0.02%	270
2024 Q4	$6.61M	Buy	164,263 +54,814	+50%	+$3.13M	0.03%	241
2024 Q3	$6.93M	Buy	109,449 +58,000	+113%	+$3.4M	0.04%	242
2024 Q2	$2.73M	Sell	51,449 -956	-2%	-$62.7K	0.02%	328
2024 Q1	$4.3M	Buy	+52,405	New	+$2.33M	0.02%	282

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AGF Management's VKTX Position: Q2 2025 in Review

AGF Management sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 178,185 shares — an estimated $4.3M sold.

AGF Management first reported a position in VKTX in Q1 2024 and held it in 5 quarters. The position peaked at $6.93M in Q3 2024. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

AGF Management reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
AGF Management sold 178,185 Viking Therapeutics shares in Q2 2025, an estimated $4.3M.
AGF Management first reported a position in Viking Therapeutics in Q1 2024 and held it in 5 quarters.
AGF Management's Viking Therapeutics position peaked at $6.93M in Q3 2024.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on AGF Management's 13F filing for Q2 2025, filed 6 Aug 2025.